Estimating the prevalence of poor-quality anti-TB medicines: a neglected risk for global TB control and resistance.

Published in: BMJ global health (2023)

SF, especially substandard, anti-TB medicines are present worldwide. However, TB medicine quality data are few and are therefore not generalisable that 15.2% of global anti-TB medicine supply is SF. The evidence available suggests that the surveillance of the quality of TB medicines needs to be an integral part of treatment programmes. More research is needed on the development and evaluation of rapid, affordable and accurate portable devices to empower pharmacy inspectors to screen for anti-TB medicines.

Keyphrases

mycobacterium tuberculosis
quality improvement
risk factors
high resolution
high throughput
big data
machine learning
mass spectrometry
combination therapy
data analysis